FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126024001> ?p ?o ?g. }

• W2126024001 endingPage "42065" @default.
• W2126024001 startingPage "42060" @default.
• W2126024001 abstract "Neurofibrillary tangles (NFTs) are found in a wide range of neurodegenerative disorders, including Alzheimer's disease. The major component of NFTs is aberrantly hyperphosphorylated microtubule-associated protein tau. Because appropriate in vivo models have been lacking, the role of tau phosphorylation in NFTs formation has remained elusive. Here, we describe a new model in which adenovirus-mediated gene expression of tau, ΔMEKK, JNK3, and GSK-3β in COS-7 cells produces most of the pathological phosphorylation epitopes of tau including AT100. Furthermore, this co-expression resulted in the formation of tau aggregates having short fibrils that were detergent-insoluble and Thioflavin-S-reactive. These results suggest that aberrant tau phosphorylation by the combination of these kinases may be involved in “pretangle,” oligomeric tau fibril formation in vivo. Neurofibrillary tangles (NFTs) are found in a wide range of neurodegenerative disorders, including Alzheimer's disease. The major component of NFTs is aberrantly hyperphosphorylated microtubule-associated protein tau. Because appropriate in vivo models have been lacking, the role of tau phosphorylation in NFTs formation has remained elusive. Here, we describe a new model in which adenovirus-mediated gene expression of tau, ΔMEKK, JNK3, and GSK-3β in COS-7 cells produces most of the pathological phosphorylation epitopes of tau including AT100. Furthermore, this co-expression resulted in the formation of tau aggregates having short fibrils that were detergent-insoluble and Thioflavin-S-reactive. These results suggest that aberrant tau phosphorylation by the combination of these kinases may be involved in “pretangle,” oligomeric tau fibril formation in vivo. neurofibrillary tangle Alzheimer's disease stress-activated protein kinase c-Jun N-terminal kinase paired helical filament mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase glycogen synthase kinase-3β phosphate-buffered saline radioimmune precipitation assay Filamentous tau aggregates is the major component of neurofibrillary tangles (NFTs)1 (1Lee V.M. Trojanowski J.Q. Neuron. 1999; 24: 507-510Abstract Full Text Full Text PDF PubMed Scopus (90) Google Scholar), the most common neuropathological hallmark in several neurodegenerative disorders, including Alzheimer's disease (AD). Discovery of the molecular mechanisms of NFT formation may provide more direct insight into the process of neurodegeneration in AD. NFTs consist of highly phosphorylated microtubule-associated protein tau that assembles to form fibrils with β-sheet structures within the cell body and dendrites of neurons (2Grundke-Iqbal I. Iqbal K. Tung Y.C. Quinlan M. Wisniewski H.M. Binder L.I. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 4913-4917Crossref PubMed Scopus (2896) Google Scholar, 3Ihara Y. Nukina N. Miura R. Ogawara M. J Biochem. (Tokyo). 1986; 99: 1807-1810Crossref PubMed Scopus (430) Google Scholar). Several in vitro studies reveal that the repeat domain of tau aggregates more readily than full-length tau (4Wille H. Drewes G. Biernat J. Mandelkow E.M. Mandelkow E. J. Cell Biol. 1992; 118: 573-584Crossref PubMed Scopus (425) Google Scholar, 5Schweers O. Mandelkow E.M. Biernat J. Mandelkow E. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 8463-8467Crossref PubMed Scopus (351) Google Scholar) and forms the core of tau fibrils in AD (6Wischik C.M. Novak M. Thogersen H.C. Edwards P.C. Runswick M.J. Jakes R. Walker J.E. Milstein C. Roth M. Klug A. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 4506-4510Crossref PubMed Scopus (780) Google Scholar). Moreover, this aggregate formation is enhanced by the existence of a polyanion such as heparin (7Goedert M. Jakes R. Spillantini M.G. Hasegawa M. Smith M.J. Crowther R.A. Nature. 1996; 383: 550-553Crossref PubMed Scopus (870) Google Scholar, 8Perez M. Valpuesta J.M. Medina M. Montejo de Garcini E. Avila J. J. Neurochem. 1996; 67: 1183-1190Crossref PubMed Scopus (375) Google Scholar) or by RNA (9Kampers T. Friedhoff P. Biernat J. Mandelkow E.M. Mandelkow E. FEBS Lett. 1996; 399: 344-349Crossref PubMed Scopus (430) Google Scholar) or fatty acids (10Wilson D.M. Binder L.I. Am. J. Pathol. 1997; 150: 2181-2195PubMed Google Scholar) in the absence of tau phosphorylation. However, these in vitro conditions may not be relevant to the mechanism underlying the formation of NFTs, because tau is always aberrantly hyperphosphorylated in AD. Therefore, it would seem necessary to consider the role of hyperphosphorylation of tau in the abnormal aggregation of filamentous tau. The assembly of phosphorylated tau was also observed during the presence of 4-hydoroxy-2-nonenal (11Perez M. Cuadros R. Smith M.A. Perry G. Avila J. FEBS Lett. 2000; 486: 270-274Crossref PubMed Scopus (108) Google Scholar), a lipid peroxidation by-product of oxidative stress. Increased oxidative stress is reported to occur in AD (12Perry G. Roder H. Nunomura A. Takeda A. Friedlich A.L. Zhu X. Raina A.K. Holbrook N. Siedlak S.L. Harris P.L. Smith M.A. Neuroreport. 1999; 10: 2411-2415Crossref PubMed Scopus (259) Google Scholar, 13Behl C. Prog. Neurobiol. 1999; 57: 301-323Crossref PubMed Scopus (405) Google Scholar, 14Perry G. Raina A.K. Nunomura A. Wataya T. Sayre L.M. Smith M.A. Free Radic. Biol. Med. 2000; 28: 831-834Crossref PubMed Scopus (250) Google Scholar, 15Sayre L.M. Perry G. Harris P.L. Liu Y. Schubert K.A. Smith M.A. J. Neurochem. 2000; 74: 270-279Crossref PubMed Scopus (477) Google Scholar). Interestingly, phospho-tau immunoreactive neurons are also stained positively with 8-hydroxy-oxyguanine, another marker for oxidative stress (16Nunomura A. Perry G. Pappolla M.A. Wade R. Hirai K. Chiba S. Smith M.A. J. Neurosci. 1999; 19: 1959-1964Crossref PubMed Google Scholar, 17Nunomura A. Perry G. Aliev G. Hirai K. Takeda A. Balraj E.K. Jones P.K. Ghanbari H. Wataya T. Shimohama S. Chiba S. Atwood C.S. Petersen R.B. Smith M.A. J. Neuropathol. Exp. Neurol. 2001; 60: 759-767Crossref PubMed Scopus (1605) Google Scholar). These results suggest that oxidative stress may, in part, trigger the formation of NFTs. If oxidative stress does participate in NFTs formation in AD, such stress can lead to the activation of kinases that phosphorylate tau and stimulate NFT formation. One such candidate kinase is stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), a member of the mitogen-activated protein kinase family that is activated by several kinase cascades. Recent studies, employing antibodies against paired helical filaments (PHFs), have reported that activated phospho-JNK co-localized in neurons displaying PHF immunoreactivities (18Mohit A.A. Martin J.H. Miller C.A. Neuron. 1995; 14: 67-78Abstract Full Text PDF PubMed Scopus (187) Google Scholar, 19Zhu X. Raina A.K. Rottkamp C.A. Aliev G. Perry G. Boux H. Smith M.A. J. Neurochem. 2001; 76: 435-441Crossref PubMed Scopus (375) Google Scholar). Phospho-JNK was also shown to translocate from the nucleus to the cytoplasm in NFT-bearing neurons (19Zhu X. Raina A.K. Rottkamp C.A. Aliev G. Perry G. Boux H. Smith M.A. J. Neurochem. 2001; 76: 435-441Crossref PubMed Scopus (375) Google Scholar). Furthermore, JNK has been shown to phosphorylate tau at Ser422 (20Goedert M. Hasegawa M. Jakes R. Lawler S. Cuenda A. Cohen P. FEBS Lett. 1997; 409: 57-62Crossref PubMed Scopus (261) Google Scholar), a site that is specifically phosphorylated in AD brains (21Zheng-Fischhofer Q. Biernat J. Mandelkow E.M. Illenberger S. Godemann R. Mandelkow E. Eur. J. Biochem. 1998; 252: 542-552Crossref PubMed Scopus (291) Google Scholar). To understand the role of tau phosphorylation in NFT formation, we sought to develop a model that could reproduce the aberrant tau phosphorylation, including phosphorylation of Thr212 and Ser214, key sites commonly referred to as the AT100 epitope. The AT100 epitope appears to be more specific for Alzheimer tau and required more than one kinase to be accomplished in vitro (22Hasegawa M. Morishima-Kawashima M. Takio K. Suzuki M. Titani K. Ihara Y. J. Biol. Chem. 1992; 267: 17047-17054Abstract Full Text PDF PubMed Google Scholar). In the present study, we used an adenovirus-mediated gene expression system to synergistically express tau, ΔMEKK, JNK3, and GSK-3β. This system enabled us to produce hyperphosphorylation of tau in cultured cells including that at AT100 and PS422. This hyperphosphorylated tau formed aggregates that were detergent-insoluble and Thioflavin-S-reactive and displayed relatively shorter fibrils than PHF. Our results suggest that the aberrant phosphorylation of tau can contribute to the formation of oligomeric tau fibrils and that other additional factors may be required for the growth step of tau fibrils. All transcription units were ligated into cassette cosmid pAxCAwt (TaKaRa) digested withSwaI, so that the insert was transcribed under the control of the CAG promoter (23Niwa H. Yamamura K. Miyazaki J. Gene (Amst.). 1991; 108: 193-199Crossref PubMed Scopus (4617) Google Scholar). Using PCR and Pyrobest DNA polymerase (TaKaRa) with pFLAG-CMV2-JNK3 (24Ito M. Yoshioka K. Akechi M. Yamashita S. Takamatsu N. Sugiyama K. Hibi M. Nakabeppu Y. Shiba T. Yamamoto K.I. Mol. Cell. Biol. 1999; 19: 7539-7548Crossref PubMed Scopus (228) Google Scholar) as a template, the mouse JNK3 open reading frame was amplified along with the FLAG tag primer (5′-ACCATGGACTACAAAGACGATGACGAC-3′) and the arm primer of these expression vectors (5′-GCACTGGAGTGGCAACTTC-3′). pcDNA3-FLAG-ΔMEKK (24Ito M. Yoshioka K. Akechi M. Yamashita S. Takamatsu N. Sugiyama K. Hibi M. Nakabeppu Y. Shiba T. Yamamoto K.I. Mol. Cell. Biol. 1999; 19: 7539-7548Crossref PubMed Scopus (228) Google Scholar), which encodes residues 1169–1488 of mouse MEKK1, was used as a template to generate pAxCA-FLAG-ΔMEKK via PCR and the FLAG tag primer and ΔMEKK-ter primer (5′-CTACCACGTGGTACGGAAG-3′). Human wild type GSK-3β cDNA, tagged with a Myc epitope at the carboxyl terminus, was cloned into the pCIneo vector (Promega). The GSK-3β open reading frame was excised by EcoRI digestion from pCIneo-GSK-3β, blunt-ended, and cloned into pAxCAwt at theSwaI site (designated pAxCA-GSK-3β). Human wild type Tau four-repeat (Tau4RWT) cDNA, tagged with a FLAG epitope at the amino-terminal and a Myc epitope at the carboxyl terminus, was cloned into pCIneo. The Tau4RWT open reading frame was excised byXhoI and NotI digestion from pCIneo-Tau4RWT, blunt-ended, and then inserted into pAxCAwt at the SwaI site (designated pAxCA-Tau4RWT). These resulting cosmid clones were used to generate recombinant adenoviruses (designated AxCA vector) using the COS-TPC method (25Miyake S. Makimura M. Kanegae Y. Harada S. Sato Y. Takamori K. Tokuda C. Saito I. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 1320-1324Crossref PubMed Scopus (788) Google Scholar). Briefly, cosmid DNA was co-transfected with theEcoT221-digested DNA-terminal protein complex of Ad-dlX (26Saito I. Oya Y. Yamamoto K. Yuasa T. Shimojo H. J. Virol. 1985; 54: 711-719Crossref PubMed Google Scholar) into human embryonic kidney 293 cells to generate the recombinant viruses via homologous recombination. These recombinant viruses were propagated in 293 cells. After the third propagation, viruses were extracted from the 293 cells, purified using a double cesium step gradient purification (27Kanegae Y. Makimura M. Saito I. Jpn. J. Med. Sci. Biol. 1994; 47: 157-166Crossref PubMed Scopus (431) Google Scholar), dialyzed against a vehicle solution containing 10% glycerol in PBS (pH 7.4), and stored at −80 °C. Titers of the recombinant viruses were determined with the modified end point cytopathic effect assay and 293 cells (27Kanegae Y. Makimura M. Saito I. Jpn. J. Med. Sci. Biol. 1994; 47: 157-166Crossref PubMed Scopus (431) Google Scholar). Titers were expressed in plaque-forming units. Positive expression of the inserted gene product was confirmed by Western blot analysis using COS-7 cells. Adenoviruses containing JNK3, ΔMEKK, GSK-3β, Tau4RWT, and LacZ were named AxCA-JNK3, AxCA-ΔMEKK, AxCA-GSK-3β, AxCA-Tau4RWT, and AxCAi-LacZ, respectively. COS-7 cells were exposed to recombinant adenovirus at various multiplicities of infection (MOI) in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum. 48 h after infection, cells were washed once with PBS and harvested. Cells were lysed with RIPA buffer (50 mmTris-HCl (pH 8.0), 150 mm NaCl, 5 mm EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1% SDS, 5 mm 4-(2-aminoethyl) benzene-sulfonyl fluoride hydrochloride, 2 ng/ml aprotinin, 5 ng/ml leupeptin, 5 ng/ml pepstatin A, 1 mm NaF, 1 mmNa3VO4, and 1 mmβ-glycerophosphate). Cell lysates were briefly sonicated, and then protein concentrations were determined using the BCA method (Pierce). 5–30 μg of total protein per lane were separated on 8% SDS-PAGE gels and transferred to polyvinylidene difluoride membrane (Millipore Corp.). The blotted membranes were blocked with 5% skimmed milk in PBS containing 0.05% Tween 20 (PBST) for 1 h at room temperature, washed with PBST, and then incubated for 2 h at room temperature with primary antibodies. A variety of different primary antibodies and dilutions were used during these experiments. Anti-JNK3/SAPKβ (Upstate Biotechnology UK, Ltd., Buckingham, UK), 1:3000; anti-phospho-specific JNK (Promega), 1:5000; purified rabbit polyclonal phospho-independent anti-TauC (specific to tau at residues 422–438); and phospho-dependent anti-PS199, PT205, PS231, PS262, PS396, PS404, and PS422 antibodies (specific to tau at the phosphorylated residues indicated) were used as described previously (28Ishiguro K. Sato K. Takamatsu M. Park J. Uchida T. Imahori K. Neurosci. Lett. 1995; 202: 81-84Crossref PubMed Scopus (82) Google Scholar). AT8 (specific to tau doubly phosphorylated at residues Ser202 and Thr205) (29Goedert M. Jakes R. Vanmechelen E. Neurosci. Lett. 1995; 189: 167-169Crossref PubMed Scopus (481) Google Scholar), 1:100; AT100 (specific to Tau doubly phosphorylated at residues Thr212 and Ser214) (22Hasegawa M. Morishima-Kawashima M. Takio K. Suzuki M. Titani K. Ihara Y. J. Biol. Chem. 1992; 267: 17047-17054Abstract Full Text PDF PubMed Google Scholar), 1:80; AT180 (specific to tau doubly phosphorylated at residues Thr231 and Ser235) (30Goedert M. Jakes R. Crowther R.A. Cohen P. Vanmechelen E. Vandermeeren M. Cras P. Biochem. J. 1994; 301: 871-877Crossref PubMed Scopus (349) Google Scholar), 1:100, and AT270 (specific to tau phosphorylated at residue Thr181) (30Goedert M. Jakes R. Crowther R.A. Cohen P. Vanmechelen E. Vandermeeren M. Cras P. Biochem. J. 1994; 301: 871-877Crossref PubMed Scopus (349) Google Scholar), 1:500, were all purchased from Innogenetics (Ghent, Belgium). Tau-1 (specific to tau dephosphorylated at residues Ser195, Ser198, Ser199, Ser202, and Thr205) (31Binder L.I. Frankfurter A. Rebhun L.I. J. Cell Biol. 1985; 101: 1371-1378Crossref PubMed Scopus (1249) Google Scholar, 32Szendrei G.I. Lee V.M. Otvos Jr., L. J. Neurosci. Res. 1993; 34: 243-249Crossref PubMed Scopus (193) Google Scholar), 1:5000 (Roche Molecular Biochemicals), was also used. After primary antibody incubation, the membranes were washed with PBST three times and incubated with either goat anti-mouse or goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) at a dilution of 1:5000 for 1 h at room temperature. In cases showing mobility shifts of phosphorylated tau, the membranes were reincubated with goat anti-mouse or goat anti-rabbit alkaline phosphatase-conjugated secondary antibodies (Promega) at a dilution of 1:7500 for 1 h at room temperature. After washing with PBST three times, the bands were visualized by the ECL system (AmershamBiosciences). Images were documented with a LAS-1000 luminescent image analyzer (Fuji Films). For quantification of proteins on immunoblots, serial dilutions of cell lysates were loaded onto gels to obtain a calibration curve, which allowed reliable quantification. All bands were quantified using the proprietary software, Image Gauge (version 3.0) (Fuji Films Science Lab 97). Statistical analyses were performed using one-factor analysis of variance (p < 0.01), followed by post hoc pairwise comparisons using Fisher's protected least significant differences. In all bar graphs, error bars indicate the S.E. of three separate experiments, whereas ** and * represent significant differences of p < 0.001 andp < 0.01, respectively. COS-7 cells infected with recombinant adenoviruses were lysed with RIPA buffer containing 1% SDS. 2 mg of cell lysate were centrifuged for 20 min at 100,000 × g at 4 °C. The resulting pellet was washed four times with 300 μl of RIPA buffer using a sonic homogenizer. The insoluble pellet was solubilized in 70% formic acid for use in the immunoblot analysis or resuspended in 100 mmTris-HCl (pH 8.3) for examination using electron microscopy. Following centrifugation for 20 min at 100,000 × g at 4 °C, the formic acid fraction was collected, air-dried, and subjected to immunoblot analysis after suspension in SDS gel loading buffer. The samples were resolved on 8% SDS-PAGE gels, transferred onto a polyvinylidene difluoride membrane, and isolated, and insoluble tau was identified with the TauC antibody, as mentioned above. For double immunohistochemistry, cell preparation and immunohistochemical staining was performed as previously described (33Chui D.H. Shirotani K. Tanahashi H. Akiyama H. Ozawa K. Kunishita T. Takahashi K. Makifuchi T. Tabira T. J. Neurosci. Res. 1998; 53: 99-106Crossref PubMed Scopus (38) Google Scholar, 34Chui D.H. Tanahashi H. Ozawa K. Ikeda S. Checler F. Ueda O. Suzuki H. Araki W. Inoue H. Shirotani K. Takahashi K. Gallyas F. Tabira T. Nat. Med. 1999; 5: 560-564Crossref PubMed Scopus (321) Google Scholar). Briefly, cells in culture dishes were fixed with 4% paraformaldehyde for 4 min and then with cold methanol-acetone (1:2) for 6 min. The fixed cells were incubated with anti-AT8 (1:400) for 3 h at 4 °C followed by incubation with the secondary antibody, Texas Red-conjugated goat anti-mouse IgG (Capple) for 30 min at room temperature. The cells were subsequently double-labeled using standard Thioflavin-S histochemistry. The stained cells were mounted in PBS-glycerin (1:9) and analyzed with a fluorescence microscope. For immunoelectron microscopy, the RIPA-insoluble pellet that was resuspended in 100 mm Tris-HCl (pH 8.3) (see above) was absorbed onto glow-charged supporting membranes placed on 300-mesh grids. After three washes with 100 mm phosphate buffer, treated samples were incubated overnight at 4 °C in primary antibody solution containing either AT8 (1:20) or AT100 (1:40) or no antibody (for negative control) diluted in 100 mm Tris-HCl (pH 8.3). After washing, the samples were incubated with colloidal-gold conjugated secondary antibody (5 nm in diameter; 1:50, British BioCell International) for 2 h, fixed with 2% glutaraldehyde in 100 mm phosphate buffer for 5 min, negatively stained with neutralized 2% sodium phosphotungstic acid, and examined with an electron microscope (LEO 912AB, LEO Electron Microscopy, Ltd.). The cell pellets were suspended in 4% paraformaldehyde, 0.2% glutaraldehyde in 0.1 m phosphate buffer for 4 h at 4 °C. After washing, cells were embedded in 3% agarose, and then the samples were cut into 0.5-mm3 blocks. The sample blocks were cryoprotected by immersion in graded concentrations of glycerol (10, 20, and 30%) in 0.1 m phosphate buffer. The slices were plunged rapidly into liquid propane (−184 °C) by using a Leica EM CPC rapid freezing unit (Reichert, Vienna, Austria). The sections were dehydrated in 0.5% uranyl acetate dissolved in anhydrous methanol for 48 h at −90 °C followed by raising of the temperature in steps of 4 °C/h from −90 to −45 °C in a Leica AFS cryosubstitution unit (Reichert). After washing with anhydrous methanol, the sections were infiltrated with Lowicryl HM20 resin (Polyscience, Inc., Warrington, PA) with a progressive increase in the ratio of resin to methanol and polymerized with ultraviolet light (360 nm) for 24 h at −45 °C. For immunostaining, ultrathin sections (70–80 nm) mounted on nickel grids were incubated with saturated sodium (meta)periodate for 20 min. After washing, the sections were incubated with 5% normal goat serum in washing buffer (0.1 mTris-buffered saline, pH 7.4, containing 1% bovine serum albumin and 0.1% gelatin) for 20 min and then with primary antibody (anti-TauC, 1:50 dilution) overnight at 4 °C. The sections were then washed with washing buffer and incubated with 5-nm colloidal gold-conjugated secondary antibody for 2 h. After a thorough wash, the sections were counterstained and examined electron-microscopically (LEO 912AB, LEO, Oberkochen, Germany). Because JNK is activated through ΔMEKK (35Yan M. Dai T. Deak J.C. Kyriakis J.M. Zon L.I. Woodgett J.R. Templeton D.J. Nature. 1994; 372: 798-800Crossref PubMed Scopus (660) Google Scholar, 36Minden A. Lin A. McMahon M. Lange-Carter C. Derijard B. Davis R.J. Johnson G.L. Karin M. Science. 1994; 266: 1719-1723Crossref PubMed Scopus (1012) Google Scholar, 37Lin A. Minden A. Martinetto H. Claret F.X. Lange-Carter C. Mercurio F. Johnson G.L. Karin M. Science. 1995; 268: 286-290Crossref PubMed Scopus (714) Google Scholar, 38Xia Y., Wu, Z., Su, B. Murray B. Karin M. Genes Dev. 1998; 12: 3369-3381Crossref PubMed Scopus (177) Google Scholar), we first investigated the ability of JNK3 to phosphorylate tau in the presence or absence of ΔMEKK (Fig. 1). Four different combinations of cDNAs (longest human tau with JNK3 and/or ΔMEKK or with LacZ) were introduced into COS-7 cells by using the adenovirus-mediating gene transfer method (Fig. 1). All of the cells expressed significant levels of tau, JNK3, ΔMEKK, and/or LacZ (100% expression efficiency was obtained when the MOI of each construct used was over 10; data not shown). Cells co-expressing tau and JNK3 exhibited only negligible levels of activated forms of JNK (Fig.1 B, lane 1). In contrast, cells co-expressing tau, JNK3, and ΔMEKK exhibited significant levels of activated JNK (Fig. 1 B, lane 2). JNK activation by ΔMEKK was associated with the reduced mobility of tau in SDS-PAGE and the reduced Tau-1-immunoreactivity (Fig. 1,C and D, lane 2) when compared with those in cells co-expressing tau with JNK3 alone, ΔMEKK alone, or LacZ (Fig. 1, lanes 1, 3, and 4). These results suggest that ΔMEKK activation is required for JNK3 to phosphorylate tau in COS-7 cells. We further analyzed phosphorylated tau epitopes in cells co-expressing tau, JNK3, and ΔMEKK using the well characterized phosphorylation dependent anti-tau antibodies PS199, PT205, PT231, PS262, PS396, PS404, PS422, AT8, AT100, AT180, and AT270 (Fig. 2). The level of tau phosphorylation at each site was quantified as a ratio of immunoreactivity of each antibody to that of phospho-independent tau antibody TauC (Fig. 2 a). Images of Western blots are shown in the lower panels of Fig. 2, and the graphs showing the corresponding quantification are shown in theupper panels. The levels of phosphorylation at PT205, PT231, PS396, AT8, AT180, AT270, PS422, and AT100 sites were significantly increased in cells expressing activated JNK3 (Fig. 2,b–i). In particular, tau phosphorylation at PT205, AT8, and PS422 was dramatically increased in response to JNK3 activation. Activation of JNK3 by ΔMEKK (MOI = 100) resulted in a 77-fold increase in PT205 immunoreactivity, an 81-fold increase in AT8 immunoreactivity, and a 330-fold increase in PS422 immunoreactivity (Fig. 2, b, e, and h, lane 3, respectively) when compared with those from cells co-infected with LacZ (MOI = 100). AT100 immunoreactivity in these cells displayed an 18-fold increase over that in control cells expressing LacZ (Fig. 2 i, lane 3). Interestingly, AT100 as well as PS422 epitopes are known to be more specific in Alzheimer tau (21Zheng-Fischhofer Q. Biernat J. Mandelkow E.M. Illenberger S. Godemann R. Mandelkow E. Eur. J. Biochem. 1998; 252: 542-552Crossref PubMed Scopus (291) Google Scholar, 22Hasegawa M. Morishima-Kawashima M. Takio K. Suzuki M. Titani K. Ihara Y. J. Biol. Chem. 1992; 267: 17047-17054Abstract Full Text PDF PubMed Google Scholar). The immunoreactivities of PT231, PS396, AT180, and AT270 in activated JNK3-expressing cells (Fig. 2,c, d, f, and g,lane 3, respectively) exhibited 3–5-fold increases over those in control cells. PS199, PS262, and PS404 immunoreactivities increased only 1–1.8-fold, suggesting that these epitopes are not major phosphorylation sites for JNK3 (Fig. 2,j–l, lane 3, respectively). Thus, with JNK3 activation, the Ser202, Thr205, and Ser422 sites were most susceptible, the Thr212and Ser214 sites were moderately susceptible, and the Thr181, Thr231, Ser235, and Ser396 sites were relatively less but significantly susceptible to JNK3-mediated phosphorylation. The Ser199, Ser262, and Ser404 sites appear to be unsusceptible to JNK3 phosphorylation. JNK3 phosphorylates tau at most of the pathological sites except Ser199, Ser262, and Ser404. These JNK3-sensitive or -insensitive sites overlapped with those reported in a previous in vitro study using recombinant proteins (39Reynolds C.H. Betts J.C. Blackstock W.P. Nebreda A.R. Anderton B.H. J. Neurochem. 2000; 74: 1587-1595Crossref PubMed Scopus (315) Google Scholar). In the same study, GSK-3β was reported to phosphorylate some of the JNK-insensitive sites. Motivated by this finding, we next attempted to simultaneously express tau, ΔMEKK, JNK3, and GSK-3β in COS-7 cells to determine the effect of simultaneous overexpression of activated JNK3 and GSK-3β on tau phosphorylation in our model. We refer to this co-expression as quadruple expression in this paper. Fig. 3 a shows a result from the Western blot analysis probed with the phospho-independent anti-tau antibody TauC. With quadruple expression, tau migrated more slowly almost as a single band than tau phosphorylated solely by activated JNK3 (Fig. 3 a, lanes 1 and2), suggesting that additional overexpression of GSK-3β to activated JNK3 causes additive effect on tau phosphorylation in COS-7 cells. The Western blot analysis using the PS199, PS262, and PS404 antibodies indicated the enhanced phosphorylation at these JNK3-insensitive sites (Fig. 3, b–d). Moreover, other sites also displayed enhanced phosphorylation in response to additional GSK-3β expression. For example, the immunoreactivities of AT8 (Fig.3 g), AT180 (Fig. 3 e), and AT100 (Fig.3 i) with quadruple expression increased 2–3.4-fold compared with those with activated JNK3 expression alone. In contrast, additional GSK-3β expression had no significant additive effect on the AT270 (Fig. 3 f) and PS422 (Fig. 3 h) immunoreactivities. Taken together, activated JNK3 and GSK-3β synergistically phosphorylated tau at most of the pathological phosphorylation sites of tau in COS-7 cells. To determine whether this quadruple expression in COS-7 cells induces aberrant tau aggregates, cells were stained with the phospho-dependent anti-tau antibody AT8 (Fig.4 b) and Thioflavin-S histochemistry (Fig. 4 a). Thioflavin-S is known as a marker for the insoluble protein aggregates with β-pleated sheets, as is shown in Fig. 4 g, displaying an NFT-bearing neuron in an AD brain. AT8 staining was confined mainly to the cytoplasm of quadruple expressing cells. Some of these cells exhibited Thioflavin-S staining in the cytoplasm, probably showing a partial aggregation of hyperphosphorylated tau in these cells (Fig. 4, a–c). We never found Thioflavin-S staining in tau/JNK3/ΔMEKK-, tau/GSK-3β-, and tau/LacZ-expressing cells (Fig. 4, d–f). These data suggest that some cells simultaneously expressing tau, activated-JNK3, and GSK-3β occasionally form aggregates of hyperphosphorylated tau with β-sheet structures. We further investigated biochemically whether hyperphosphorylated tau formed insoluble fibrillar aggregates. Lysates from cells co-expressing tau, ΔMEKK, JNK3, and/or GSK-3β were dissolved in RIPA (containing 1% SDS) buffer, and both RIPA-soluble and -insoluble fractions were analyzed. Fig. 5 a shows an immunoblot of the RIPA-soluble fractions probed with the phospho-independent anti-tau antibody TauC. Although the total amounts of tau recovered in the RIPA-soluble fractions were almost constant, mobility of tau in each lane changed depending on the combination of kinases expressed. RIPA-insoluble materials were next solubilized using 70% formic acid and dissolved into Laemmli sample buffer after lyophilization. Only tau from quadruple-expressing cells was recovered in the formic acid fraction (Fig. 5 b), suggesting that tau from quadruple-expressing cells becomes partly insoluble in RIPA (containing 1% SDS). The ultrastructure of immunolabeled RIPA insoluble materials from quadruple expressing cells and AD brains were investigated by using the electron microscope. We found RIPA-insoluble tau filaments from AD brains identified with the AT8 and AT100 antibodies (Fig. 5,c and e, respectively) that had two different shapes with different diameters: short fibrils with 10-nm diameter (Fig. 5 c) and relatively longer fibrils with 20-nm diameter (Fig. 5 e). Consistent with this observation, in the RIPA-insoluble fractions of quadruple-expressing cells, the AT8- and AT100-positive tau aggregates were identified that contain short fibril-like structures with about 10-nm diameters (Fig. 5, dand f, respectively). The similar tau aggregates were found in the perinuclear regions of the quadruple expressing cells (Fig.5 g) but not in control cells expressing tau and LacZ (Fig.5 h). These data suggest that hyperphosphorylation of tau by GSK-3β and activated JNK3 could enforce the formation of tau aggregates sometimes containing short fibrils. In this report, we demonstrate that activated JNK3 phosphorylates tau in COS-7 cells. This kinase increases levels of tau phosphorylation at the epitopes of PT205, PT231, PS396, PS422, AT8, AT100, AT180, and AT270. This is almost consistent with the results obtained from thein vitro studies (40Reynolds C.H. Utton M.A. Gibb G.M. Yates A. Anderton B.H. J. Neurochem. 1997; 68: 1736-1744Crossref PubMed Scopus (193) Google Scholar). The combination of activated JNK3 and GSK-3β cooperatively phosphorylates 12 Ser and Thr residues of tauin vivo. These include the AT100 site, which is the specific phosphorylation site in PHF tau. There are more than 19 phosphorylation sites identified in PHF tau (41Morishima-Kawashima M. Hasegawa M. Takio K. Suzuki M. Yoshida H. Titani K. Ihara Y. J. Biol. Chem. 1995; 270: 823-829Abstract Full Text Full Text PDF PubMed Scopus (529) Google Scholar). Most phosphorylation-dependent tau antibodies, however, also have been known to recognize a fraction of tau from biopsied normal adult or fetal brains, although the levels of phosphorylation are less than those recognized in AD brains (42Matsuo E.S. Shin R.W. Billingsley M.L. Van deVoorde A. O'Connor M. Trojanowski J.Q. Lee V.M. Neuron. 1994; 13: 989-1002Abstract Full Text PDF PubMed Scopus (555) Google Scholar). Among these antibodies, AT100 never recognizes normal adult or fetal tau but does specifically recognize PHF tau (22Hasegawa M. Morishima-Kawashima M. Takio K. Suzuki M. Titani K. Ihara Y. J. Biol. Chem. 1992; 267: 17047-17054Abstract Full Text PDF PubMed Google Scholar, 42Matsuo E.S. Shin R.W. Billingsley M.L. Van deVoorde A. O'Connor M. Trojanowski J.Q. Lee V.M. Neuron. 1994; 13: 989-1002Abstract Full Text PDF PubMed Scopus (555) Google Scholar). Thus, the AT100 epitope is a unique and specific phosphorylation site in PHF tau. In this sense, tau in quadruple expressing cells is in a similar phosphorylation state to that in AD. The in vitro phosphorylation of AT100 epitope was reported by using the combination of protein kinase A and GSK-3β (22Hasegawa M. Morishima-Kawashima M. Takio K. Suzuki M. Titani K. Ihara Y. J. Biol. Chem. 1992; 267: 17047-17054Abstract Full Text PDF PubMed Google Scholar). According to this study, the phosphorylation of the AT100 epitope required the sequential phosphorylation of GSK-3β and protein kinase A, although the other combination may be due to the phosphorylation of these epitopes. This combination may not be relevant to AD tau formation, because neither GSK-3β nor protein kinase A can phosphorylate Ser422, a site that is highly phosphorylated in AD brain (20Goedert M. Hasegawa M. Jakes R. Lawler S. Cuenda A. Cohen P. FEBS Lett. 1997; 409: 57-62Crossref PubMed Scopus (261) Google Scholar, 21Zheng-Fischhofer Q. Biernat J. Mandelkow E.M. Illenberger S. Godemann R. Mandelkow E. Eur. J. Biochem. 1998; 252: 542-552Crossref PubMed Scopus (291) Google Scholar). In our study, activated JNK3 phosphorylated tau both at the Ser422 and AT100 epitopes. However, activated JNK3 did not phosphorylate the Ser199, Ser262, and Ser404 sites, phosphorylation of which required the additional expression of GSK-3β. Furthermore, immunoreactivity for AT100 epitopes is much more enhanced in cells co-expressing both activated JNK3 and GSK-3β. It is also possible that the formation of AT100 epitopes in cells expressing only activated JNK3 may result from the synergism between JNK3 and endogenous GSK-3β. Thus, the combination of GSK-3β and activated JNK3 can phosphorylate tau at most of the phosphorylation sites documented in AD. Recent studies reported that activated phospho-JNK or GSK-3β co-localized in NFT-bearing (18Mohit A.A. Martin J.H. Miller C.A. Neuron. 1995; 14: 67-78Abstract Full Text PDF PubMed Scopus (187) Google Scholar, 19Zhu X. Raina A.K. Rottkamp C.A. Aliev G. Perry G. Boux H. Smith M.A. J. Neurochem. 2001; 76: 435-441Crossref PubMed Scopus (375) Google Scholar) or AT8-positive neurons (19Zhu X. Raina A.K. Rottkamp C.A. Aliev G. Perry G. Boux H. Smith M.A. J. Neurochem. 2001; 76: 435-441Crossref PubMed Scopus (375) Google Scholar, 43Shiurba R.A. Ishiguro K. Takahashi M. Sato K. Spooner E.T. Mercken M. Yoshida R. Wheelock T.R. Yanagawa H. Imahori K. Nixon R.A. Brain Res. 1996; 737: 119-132Crossref PubMed Scopus (65) Google Scholar, 44Yamaguchi H. Ishiguro K. Uchida T. Takashima A. Lemere C.A. Imahori K. Acta Neuropathol. (Berl.). 1996; 92: 232-241Crossref PubMed Scopus (237) Google Scholar), and amyloid β treatment activated JNK (45Morishima Y. Gotoh Y. Zieg J. Barrett T. Takano H. Flavell R. Davis R.J. Shirasaki Y. Greenberg M.E. J. Neurosci. 2001; 21: 7551-7560Crossref PubMed Google Scholar, 46Troy C.M. Rabacchi S.A., Xu, Z. Maroney A.C. Connors T.J. Shelanski M.L. Greene L.A. J. Neurochem. 2001; 77: 157-164Crossref PubMed Google Scholar) and GSK-3β in cultured cells (47Takashima A. Noguchi K. Sato K. Hoshino T. Imahori K. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 7789-7793Crossref PubMed Scopus (381) Google Scholar, 48Takashima A. Yamaguchi H. Noguchi K. Michel G. Ishiguro K. Sato K. Hoshino T. Hoshi M. Imahori K. Neurosci. Lett. 1995; 198: 83-86Crossref PubMed Scopus (59) Google Scholar, 49Takashima A. Honda T. Yasutake K. Michel G. Murayama O. Murayama M. Ishiguro K. Yamaguchi H. Neurosci. Res. 1998; 31: 317-323Crossref PubMed Scopus (266) Google Scholar, 50Takashima A. Murayama M. Murayama O. Kohno T. Honda T. Yasutake K. Nihonmatsu N. Mercken M. Yamaguchi H. Sugihara S. Wolozin B. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 9637-9641Crossref PubMed Scopus (401) Google Scholar). Taken together, activated JNK and GSK-3β may be a strong candidate kinase combination involved in the mechanisms of tau pathology in AD. It has been a question for a long time whether the aberrant phosphorylation of tau is a cause of NFT formation or just a consequence of some other unidentified process. One hint was provided by a recent in vitro study that showed that hyperphosphorylation of tau in AD brain induces self-assembly of tau into PHF (51Alonso A. Zaidi T. Novak M. Grundke-Iqbal I. Iqbal K. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 6923-6928Crossref PubMed Scopus (755) Google Scholar). Our present results indicate that the aberrant phosphorylation of tau results in the formation of short fibrils that are RIPA-insoluble. These fibrils were relatively shorter than reported PHF in AD brains. Since similar types of fibrils were also recovered from AD brains, tau fibrils observed in the quadruple expressing COS-7 cells might be a good model to study tau aggregation in a cellular environment. The formation of NFTs is mainly divided into three stages. First is the pretangle stage, which exhibits PHF epitopes and becomes Gallyas silver-positive. Second is the mature tangle stage, which shows PHF epitopes, Gallyas silver staining, and Thiazine Red staining, which recognizes fibrillar structures. The last is the ghost tangle stage. Our histochemical study revealed AT8 and Thioflavin-S-positive staining; Thioflavin-S is more sensitive than Thiazine Red when recognizing oligomeric fibrils with β-sheet structure (52LeVine III, H. Methods Enzymol. 1999; 309: 274-284Crossref PubMed Scopus (1213) Google Scholar). However, overall the staining pattern did not show a clear fibrillar structure, suggesting that COS-7 cells expressing both activated JNK3 and GSK-3β may mimic the neurons in the pretangle stage but not in the mature tangle stage. Thus, the aberrant phosphorylation of tau probably promotes tau oligomer formation such as seen in the pretangle stage. Other factors or certain intracellular environment are apparently required for the development of this stage to the mature one. For example, antiapoptotic factors might be such candidates, since activated JNK3 and GSK-3β have been known to activate a cascade for apoptosis. Further studies will be required to identify this tau fibril growth factors." @default.
• W2126024001 created "2016-06-24" @default.
• W2126024001 creator A5004545485 @default.
• W2126024001 creator A5005631158 @default.
• W2126024001 creator A5010788480 @default.
• W2126024001 creator A5011526572 @default.
• W2126024001 creator A5012141423 @default.
• W2126024001 creator A5020494202 @default.
• W2126024001 creator A5028881223 @default.
• W2126024001 creator A5037301114 @default.
• W2126024001 creator A5048457826 @default.
• W2126024001 creator A5055620361 @default.
• W2126024001 creator A5068377786 @default.
• W2126024001 creator A5069465815 @default.
• W2126024001 creator A5080550833 @default.
• W2126024001 date "2002-11-01" @default.
• W2126024001 modified "2023-10-16" @default.
• W2126024001 title "Aberrant Tau Phosphorylation by Glycogen Synthase Kinase-3β and JNK3 Induces Oligomeric Tau Fibrils in COS-7 Cells" @default.
• W2126024001 cites W1501075116 @default.
• W2126024001 cites W1542215809 @default.
• W2126024001 cites W1588296570 @default.
• W2126024001 cites W1598318710 @default.
• W2126024001 cites W1731253253 @default.
• W2126024001 cites W1766634805 @default.
• W2126024001 cites W1896970469 @default.
• W2126024001 cites W1929269608 @default.
• W2126024001 cites W1958842451 @default.
• W2126024001 cites W1967285029 @default.
• W2126024001 cites W1973068726 @default.
• W2126024001 cites W1976519846 @default.
• W2126024001 cites W1978668412 @default.
• W2126024001 cites W1979212852 @default.
• W2126024001 cites W1980389635 @default.
• W2126024001 cites W1982255130 @default.
• W2126024001 cites W1982390204 @default.
• W2126024001 cites W1983279909 @default.
• W2126024001 cites W1994030229 @default.
• W2126024001 cites W1994282166 @default.
• W2126024001 cites W1996766499 @default.
• W2126024001 cites W2005900169 @default.
• W2126024001 cites W2008308614 @default.
• W2126024001 cites W2018908557 @default.
• W2126024001 cites W2021667186 @default.
• W2126024001 cites W2022402045 @default.
• W2126024001 cites W2031102482 @default.
• W2126024001 cites W2031179697 @default.
• W2126024001 cites W2033089513 @default.
• W2126024001 cites W2036684416 @default.
• W2126024001 cites W2036755018 @default.
• W2126024001 cites W2036985660 @default.
• W2126024001 cites W2037230449 @default.
• W2126024001 cites W2040351396 @default.
• W2126024001 cites W2042347168 @default.
• W2126024001 cites W2048162805 @default.
• W2126024001 cites W2053695273 @default.
• W2126024001 cites W2053791137 @default.
• W2126024001 cites W2057160717 @default.
• W2126024001 cites W2058085247 @default.
• W2126024001 cites W2058570072 @default.
• W2126024001 cites W2062772621 @default.
• W2126024001 cites W2068814836 @default.
• W2126024001 cites W2070971554 @default.
• W2126024001 cites W2078658743 @default.
• W2126024001 cites W2111252945 @default.
• W2126024001 cites W2140851951 @default.
• W2126024001 cites W2160990129 @default.
• W2126024001 cites W4313635391 @default.
• W2126024001 cites W47608607 @default.
• W2126024001 cites W58149416 @default.
• W2126024001 doi "https://doi.org/10.1074/jbc.m202241200" @default.
• W2126024001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12191990" @default.
• W2126024001 hasPublicationYear "2002" @default.
• W2126024001 type Work @default.
• W2126024001 sameAs 2126024001 @default.
• W2126024001 citedByCount "118" @default.
• W2126024001 countsByYear W21260240012012 @default.
• W2126024001 countsByYear W21260240012013 @default.
• W2126024001 countsByYear W21260240012014 @default.
• W2126024001 countsByYear W21260240012015 @default.
• W2126024001 countsByYear W21260240012016 @default.
• W2126024001 countsByYear W21260240012017 @default.
• W2126024001 countsByYear W21260240012019 @default.
• W2126024001 countsByYear W21260240012020 @default.
• W2126024001 countsByYear W21260240012022 @default.
• W2126024001 countsByYear W21260240012023 @default.
• W2126024001 crossrefType "journal-article" @default.
• W2126024001 hasAuthorship W2126024001A5004545485 @default.
• W2126024001 hasAuthorship W2126024001A5005631158 @default.
• W2126024001 hasAuthorship W2126024001A5010788480 @default.
• W2126024001 hasAuthorship W2126024001A5011526572 @default.
• W2126024001 hasAuthorship W2126024001A5012141423 @default.
• W2126024001 hasAuthorship W2126024001A5020494202 @default.
• W2126024001 hasAuthorship W2126024001A5028881223 @default.
• W2126024001 hasAuthorship W2126024001A5037301114 @default.
• W2126024001 hasAuthorship W2126024001A5048457826 @default.
• W2126024001 hasAuthorship W2126024001A5055620361 @default.
• W2126024001 hasAuthorship W2126024001A5068377786 @default.
• W2126024001 hasAuthorship W2126024001A5069465815 @default.

• next